
Christopher A Maher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6719199/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Sorghum bicolor genome and the diversification of grasses. Nature, 2009, 457, 551-556.	27.8	2,642
2	Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers. Cell, 2012, 150, 1121-1134.	28.9	1,038
3	Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. Science, 2008, 322, 1695-1699.	12.6	995
4	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature Biotechnology, 2011, 29, 742-749.	17.5	950
5	Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 2012, 486, 353-360.	27.8	922
6	Transcriptome sequencing to detect gene fusions in cancer. Nature, 2009, 458, 97-101.	27.8	791
7	miR-24 Inhibits Cell Proliferation by Targeting E2F2, MYC, and Other Cell-Cycle Genes via Binding to "Seedless―3′UTR MicroRNA Recognition Elements. Molecular Cell, 2009, 35, 610-625.	9.7	544
8	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. Cell Reports, 2013, 4, 1116-1130.	6.4	539
9	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	28.9	459
10	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine, 2010, 16, 793-798.	30.7	436
11	The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nature Genetics, 2009, 41, 553-562.	21.4	408
12	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell, 2011, 19, 664-678.	16.8	397
13	A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition. Journal of Cell Biology, 2011, 195, 417-433.	5.2	390
14	Long noncoding RNAs in cancer metastasis. Nature Reviews Cancer, 2021, 21, 446-460.	28.4	342
15	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	28.9	334
16	Evolution of Arabidopsis microRNA families through duplication events. Genome Research, 2006, 16, 510-519.	5.5	328
17	A Genome-Wide Characterization of MicroRNA Genes in Maize. PLoS Genetics, 2009, 5, e1000716.	3.5	318
18	Chimeric transcript discovery by paired-end transcriptome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12353-12358.	7.1	302

#	Article	IF	CITATIONS
19	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Medicine, 2011, 17, 1646-1651.	30.7	301
20	Genome-wide analysis of cancer/testis gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20422-20427.	7.1	295
21	Common Gene Rearrangements in Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 3659-3668.	1.6	268
22	ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics, 2011, 27, 2903-2904.	4.1	241
23	Transcription Factors OVOL1 and OVOL2 Induce the Mesenchymal to Epithelial Transition in Human Cancer. PLoS ONE, 2013, 8, e76773.	2.5	229
24	Genome-wide analysis for discovery of rice microRNAs reveals natural antisense microRNAs (nat-miRNAs). Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4951-4956.	7.1	218
25	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	21.4	198
26	Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell, 2011, 20, 187-199.	16.8	191
27	Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biology, 2014, 15, 429.	8.8	179
28	Optimizing Cancer Genome Sequencing and Analysis. Cell Systems, 2015, 1, 210-223.	6.2	174
29	Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Research, 2011, 21, 1028-1041.	5.5	166
30	Chromothripsis and Human Disease: Piecing Together the Shattering Process. Cell, 2012, 148, 29-32.	28.9	141
31	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood, 2011, 117, 6172-6183.	1.4	132
32	Visualizing tumor evolution with the fishplot package for R. BMC Genomics, 2016, 17, 880.	2.8	131
33	Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. Molecular Cell, 2013, 49, 80-93.	9.7	130
34	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget, 2012, 3, 1011-1025.	1.8	126
35	INTECRATE: gene fusion discovery using whole genome and transcriptome data. Genome Research, 2016, 26, 108-118.	5.5	120
36	INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery. Bioinformatics, 2017, 33, 555-557.	4.1	105

ChristopherÂA Maher

#	Article	IF	CITATIONS
37	An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer. Molecular and Cellular Proteomics, 2016, 15, 1060-1071.	3.8	104
38	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 562-571.	1.9	104
39	Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. RNA Biology, 2015, 12, 628-642.	3.1	85
40	Genome Modeling System: A Knowledge Management Platform for Genomics. PLoS Computational Biology, 2015, 11, e1004274.	3.2	83
41	Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nature Communications, 2020, 11, 2156.	12.8	83
42	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Reports, 2018, 24, 1434-1444.e7.	6.4	73
43	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. Npj Breast Cancer, 2017, 3, 48.	5.2	63
44	Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. European Urology, 2017, 71, 257-266.	1.9	59
45	Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 1965-1976.	7.0	55
46	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clinical Cancer Research, 2019, 25, 2450-2457.	7.0	52
47	A Comparison of Single Molecule and Amplification Based Sequencing of Cancer Transcriptomes. PLoS ONE, 2011, 6, e17305.	2.5	48
48	Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3035-3040.	7.1	44
49	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Experimental Hematology, 2016, 44, 603-613.	0.4	44
50	The clonal evolution of metastatic colorectal cancer. Science Advances, 2020, 6, eaay9691.	10.3	41
51	cDNA Hybrid Capture Improves Transcriptome Analysis on Low-Input and Archived Samples. Journal of Molecular Diagnostics, 2014, 16, 440-451.	2.8	40
52	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clinical Cancer Research, 2019, 25, 4290-4299.	7.0	38
53	Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target. Molecular Cancer Therapeutics, 2012, 11, 775-783.	4.1	34
54	Loss of Long Noncoding RNA <i>NXTAR</i> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance. Cancer Research, 2022, 82, 155-168.	0.9	29

ChristopherÂA Maher

#	Article	IF	CITATIONS
55	Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget, 2014, 5, 9281-9294.	1.8	27
56	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. JCO Precision Oncology, 2021, 5, 378-388.	3.0	26
57	Cell-Free DNA Alterations in the <i>AR</i> Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer. JCO Precision Oncology, 2020, 4, 680-713.	3.0	20
58	Pan-cancer proteogenomic analysis reveals long and circular noncoding RNAs encoding peptides. NAR Cancer, 2020, 2, zcaa015.	3.1	18
59	Long, Noncoding RNA Dysregulation in Glioblastoma. Cancers, 2021, 13, 1604.	3.7	18
60	Recurrent Rearrangements in Prostate Cancer: Causes and Therapeutic Potential. Current Drug Targets, 2013, 14, 450-459.	2.1	18
61	SigFuge: single gene clustering of RNA-seq reveals differential isoform usage among cancer samples. Nucleic Acids Research, 2014, 42, e113-e113.	14.5	17
62	Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. Journal of Thoracic Oncology, 2018, 13, 1519-1529.	1.1	17
63	Heparin-based hydrogel scaffolding alters the transcriptomic profile and increases the chemoresistance of MDA-MB-231 triple-negative breast cancer cells. Biomaterials Science, 2020, 8, 2786-2796.	5.4	15
64	A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discovery. Cell Systems, 2021, 12, 827-838.e5.	6.2	15
65	Long non-coding RNA LCAL62 / LINC00261 is associated with lung adenocarcinoma prognosis. Heliyon, 2020, 6, e03521.	3.2	13
66	Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases. Molecular Cancer Therapeutics, 2021, 20, 1183-1198.	4.1	13
67	Increased breast tissue receptor activator of nuclear factor-κB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. Oncotarget, 2017, 8, 73787-73792.	1.8	12
68	A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells. Frontiers in Genetics, 2013, 4, 209.	2.3	10
69	INTEGRATE-Vis: a tool for comprehensive gene fusion visualization. Scientific Reports, 2017, 7, 17808.	3.3	10
70	Sclerosing epithelioid mesenchymal neoplasm of the pancreas–Âa proposed new entity. Modern Pathology, 2020, 33, 456-467.	5.5	10
71	Comprehensive discovery of noncoding RNAs in acute myeloid leukemia cell transcriptomes. Experimental Hematology, 2017, 55, 19-33.	0.4	9
72	Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. , 2020, 8, e001510.		9

5

ChristopherÂA Maher

#	Article	IF	CITATIONS
73	LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. Npj Breast Cancer, 2022, 8, 49.	5.2	4
74	Clonotyping for precision oncology. Drug Discovery Today, 2015, 20, 1464-1469.	6.4	3
75	SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression. Scientific Reports, 2020, 10, 15890.	3.3	3
76	Creating genetic applications for informal science learning in multi-user virtual environments. Journal of Network and Computer Applications, 2002, 25, 295-308.	9.1	2
77	Gene Fusion Discovery with INTEGRATE. Methods in Molecular Biology, 2020, 2079, 41-68.	0.9	2
78	Whole Genome Sequencing Reveals Novel Recurring Somatic Mutations Affecting HUWE1 and DIAPH2 Genes in Multiple Myeloma. Blood, 2012, 120, 320-320.	1.4	0
79	DANSR: A Tool for the Detection of Annotated and Novel Small RNAs. Non-coding RNA, 2022, 8, 9.	2.6	Ο